MedCap AB (publ) has, through its subsidiary Unimedic Pharma AB, signed an agreement to divest the rights to the product Vitamin D to Pharmaprim AB.
The sales price and capital gain amount to 20 mSEK and generates a positive one-time effect in the third quarter. In 2021, the product’s sales amounted to 3.2 mSEK and the divestment is expected to have a marginal effect on MedCap’s sales and profitability. The sale supports the focus of the company’s specialty pharma portfolio.
MedCap builds successful life sciences companies to improve people’s lives. MedCap unites the strengths of a larger the company with the smaller companies’ entrepreneurial power, agility, and business acumen. MedCap is publicly listed on NASDAQ Stockholm OMX, with the symbol MCAP. More information is available on the company web site www.medcap.se.